Chemaphor Inc. (Chemaphor) is a publicly held biotechnology company that is engaged in the development and commercialization of small-molecule compounds for animal health, skin care cosmetics, pharmaceuticals and speciality chemical markets. The company develops the products using its proprietary technology of carotenoid oxidation compounds. Its product pipeline consists of anti-cancer compounds, animal feeds, skin care cosmetics, bio active ingredients and stable isotope labelled compounds. Chemaphor currently focuses on two proprietary drugs, a non pharmaceutical product OxBC and a lead cancer drug compound OCL-1. The company is formed by the amalgamation of Occell Inc. and Triumph Acquisition Corp. Inc. Chemaphor is headquartered at Toronto in Ontario, Canada.